Tyrosol Derivatives, Bearing 3,5-Disubstituted Isoxazole and 1,4-Disubstituted Triazole, as Potential Antileukemia Agents by Promoting Apoptosis.
Antineoplastic Agents
/ pharmacology
Apoptosis
Cell Proliferation
Drug Resistance, Neoplasm
Humans
Imatinib Mesylate
/ pharmacology
Isoxazoles
/ pharmacology
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Phenylethyl Alcohol
/ analogs & derivatives
Triazoles
/ pharmacology
1,4-disubstituted triazole
3,5-disubstituted isoxazole
anti-proliferative activity
apoptosis
chronic myeloid leukemia
oxidative stress
tyrosol
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
10 Aug 2022
10 Aug 2022
Historique:
received:
05
07
2022
revised:
02
08
2022
accepted:
06
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
In the present study, we assess tyrosol derivatives bearing 3,5-disubstituted isoxazoles and 1,4-disubstituted triazoles for their ability to inhibit the proliferation of K562 cells derived from leukemia as well as primary chronic myeloid leukemia (CML) cells obtained from the peripheral blood of 15 CML patients including 10 patients with untreated chronic phase and 5 patients with resistance against imatinib or multiple TKI. Our results showed that most derivatives displayed significant anti-proliferative activity against K562 cells in a dose-dependent manner. Among them, compounds
Identifiants
pubmed: 36014333
pii: molecules27165086
doi: 10.3390/molecules27165086
pmc: PMC9415516
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Isoxazoles
0
Triazoles
0
4-hydroxyphenylethanol
1AK4MU3SNX
Imatinib Mesylate
8A1O1M485B
Phenylethyl Alcohol
ML9LGA7468
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : EU
ID : EMORI program
Références
Drug Discov Today. 2019 Jul;24(7):1355-1369
pubmed: 31102734
Bioorg Med Chem Lett. 2016 Mar 1;26(5):1419-27
pubmed: 26850004
Bioorg Chem. 2021 Sep;114:105071
pubmed: 34130108
Eur J Med Chem. 2021 Oct 5;221:113532
pubmed: 34052717
Steroids. 2019 Jul;147:10-18
pubmed: 30149075
Bioorg Med Chem. 2015 Sep 15;23(18):6157-65
pubmed: 26299825
Bioorg Med Chem Lett. 2014 Sep 1;24(17):4243-6
pubmed: 25088398
Int J Mol Sci. 2019 Dec 05;20(24):
pubmed: 31817512
Leuk Res Rep. 2019 Aug 17;12:100184
pubmed: 31485411
Cytotechnology. 2015 Oct;67(5):821-9
pubmed: 24728886
Mini Rev Med Chem. 2021;21(5):536-553
pubmed: 33109046
Eur J Med Chem. 2017 Jan 5;125:143-189
pubmed: 27662031
Handb Exp Pharmacol. 2018;249:231-250
pubmed: 29242991
Front Pharmacol. 2018 Feb 09;8:1002
pubmed: 29479316
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Antioxidants (Basel). 2021 Sep 02;10(9):
pubmed: 34573042
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1352-1361
pubmed: 30251900
Int J Mol Sci. 2020 Apr 02;21(7):
pubmed: 32252439
Bioorg Med Chem Lett. 2019 Oct 1;29(19):126577
pubmed: 31421967
Bioorg Med Chem Lett. 2016 Jun 15;26(12):2927-2930
pubmed: 27130357
Bioorg Med Chem. 2018 Jul 23;26(12):3065-3075
pubmed: 29853341
Eur J Med Chem. 2019 Dec 1;183:111700
pubmed: 31546197
Bioorg Med Chem Lett. 2020 Jul 15;30(14):127247
pubmed: 32527547